A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports | (2019) 9:20335 | www.nature.com/scientificreports Doi : 10.1038/s41598-019-56785-1 (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC [...]
Lire la suiteMedicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8 Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]
Lire la suiteQue (Devrait-on) Savoir sur la Pharmacologie du Cannabidiol ? Article rédigé par les Centres d’Addictovigilance de Grenoble, Marseille, Paris Addictovigilance, Bulletin de l’Association des Centres d’Addictovigilance, 2020, 13. www.addictovigilance.fr Messages clefs Les phyto-cannabinoïdes et les cannabinoïdes de synthèse ont des effets très variés,utiles à caractériser d’un point devue pharmacologique pour mieux préciser les effets de chacun et leurs éventuelles interactions chez l’Homme, a fortiori dans un contexte de large diffusion. Le cannabidiol (CBD) est l’un des principaux phyto-cannabinoïdes présent dans Cannabis sativa, avec le tétrahydrocannabinol (THC). Le CBD a une action pléiotropique notamment sur les récepteurs à la sérotonine, à la dopamine et pas ou très peu [...]
Lire la suiteCadre de l’expérimentation du cannabis à usage médical https://www.ansm.sante.fr/Dossiers/Cannabis-a-usage-medical/Cadre-de-l-experimentation-du-cannabis-a-usage-medical/(offset)/1 L’expérimention du cannabis à usage médical sera lancée au deuxième semestre 2020. L’objectif principal de cette phase expérimentale est d’évaluer en situation réeller le circuit de prescription et délivrance ainsi que l’adhésion des professionnels de santé et des patients à ces conditions. Son objectif secondaire est de recueillir des premières données françaises d’efficacité et de sécurité. Les éléments les plus importants de ce cadre visent à sécuriser au mieux la prescription et le suivi des patients : Sécurisation de la prescription : le traitement ne pourra être initié que par des médecins qui exercent dans [...]
Lire la suiteA tale of two cannabinoids : The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Ethan Russo & Geoffrey W. Guy Medical Hypotheses, 2006, 66, 234–246 doi : 10.1016/j.mehy.2005.08.026 Summary This study examines the current knowledge of physiological and clinical effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) and presents a rationale for their combination in pharmaceutical preparations. Cannabinoid and vanilloid receptor effects as well as non-receptor mechanisms are explored, such as the capability of THC and CBD to act as anti-inflammatory substances independent of cyclo-oxygenase (COX) inhibition. CBD is demonstrated to antagonise some undesirable effects of THC including intoxication, sedation and tachycardia, while contributing analgesic, anti-emetic, [...]
Lire la suiteChanging landscape of cannabis : novel products, formulations, and methods of administration Tory R Spindle, Marcel O Bonn-Miller and Ryan Vandrey Current Opinion in Psychology, 2019, 30, 98–102 Doi : 10.1016/j.copsyc.2019.04.002 Abstract Laws regulating cannabis have changed radically in the U.S. and abroad. Historically, users smoked dried cannabis flowers that contained D9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, as the principal product constituent. Coincident with cannabis legalization and increased interest in medicinal use of the plant, there is now an expansive retail cannabis marketplace with novel cannabis products, formulations, and methods of administration. In this review, we describe emergent cannabis product chemotypes (e.g. THC-dominant, [...]
Lire la suiteBibliographie Cannabis et Troubles cardio-vasculaires Dr Christian SUEUR, GRECC, 2e édition, janvier 2020. Actuellement, les méta-analyses ne montrent pas d'augmentation significative des pathologies cardiovasculaire chez les consommateurs de cannabis. (cf en particulier la méta-analyse de Divya RAVI et coll., Annals of Internal Medicine, 2018). Quoiqu'il en soit, l'existence de facteurs de risques liés à la consommation de cannabis fumé est semble-t-il incontestable; de même, les risques sont vraisemblablement augmentés chez les sujets prédisposés, présentant des pathologies cariaques, vasculaires, des troubles de l'excitabilité cardiaque ou de la tension artérielle. La plupart des "Case Report" consistent en des accidents par sténose vasculaire, cérébrale ou cardiaque, [...]
Lire la suiteProlonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094 The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]
Lire la suiteAs CBD Oil Flirts with Mainstream, Questions Mount Kathleen Doheny Medscape, June 11, 2018 Anxiety is a given for Jessica Singer, 25, who juggles her job at a marijuana dispensary with her night-time gigs as a stand-up comedian in Los Angeles. So when it’s time for bed, "I can't turn off my brain,'' she says. Now she does, with the help of a new bedtime ritual -- a ''snack" of two gummy bears containing CBD. CBD, or cannabidiol, is a substance from marijuana that lacks the ''high'' of the THC (tetrahydro-cannabinol) also found in marijuana. The remedy is affordable for her -- about $35 [...]
Lire la suite'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]
Lire la suite